BOSTON, March 12, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a Boston based securities litigation firm representing investors nationwide, has filed a securities fraud class action against Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) and certain of its officers alleging violations of the federal securities laws.

The Complaint, filed in the United States District Court, District of Massachusetts (Boston), located at 1 Courthouse Way, Boston, Massachusetts, 02210, and captioned Kempf v. Corbus Pharmaceutical Holdings, Inc., et al., No. 19-cv-10457, alleges that between November 14, 2016 and February 28, 2019 (the “Class Period”), Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about its drug candidate Lenabasum. A judge has not yet been assigned to the case.

If you purchased Corbus Pharmaceuticals shares during the Class Period and wish to serve as a lead plaintiff, you must move the Court no later than May 13, 2019. As a member of the class, you may seek to file a motion to serve as a lead plaintiff or take no action and remain an absent class member. If you wish to become involved in the litigation or have questions about your legal rights, you are encouraged to contact attorney Dan DeMaria at (617) 398-5660, by email at dan@blockesq.com, or by visiting http://shareholder.law/corbus.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
Dan DeMaria
(617) 398-5660 phone
155 Federal Street, Suite 400
Boston, MA 02110
dan@blockesq.com